
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
29.10.2026 11:00:00 CET | GlobeNewswire by notified | Press release
Lugano, Switzerland – October 29th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the oral suspension formulation of AKYNZEO® (netupitant/palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
The approval follows the European Commission Marketing Authorization granted earlier this year.
The oral suspension offers a new therapeutic option alongside the currently approved formulations and may provide additional flexibility and benefits to a broader range of cancer patients, including those who may have difficulty swallowing. Its approval reflects Helsinn's continued commitment to expanding therapeutic options within its supportive care portfolio and supporting patients throughout their cancer treatment journey.
Roberta Cannella, Chief Operating Officer of Helsinn,commented: “The MHRA Marketing Authorization for AKYNZEO® Oral Suspension represents another important milestone for this formulation following the European Commission authorization received in February. At Helsinn, we remain committed to advancing supportive care and addressing the evolving needs of patients and healthcare professionals through innovative treatment options.”
Commenting on the approval, Mike Crosher, UK General Manager & European Director of Portfolio and Lifecycle Management at Chugai Pharma Europe, Helsinn's commercial partner in the UK and Ireland,added: “Supportive care is an important part of helping patients manage their cancer treatment. The MHRA approval of AKYNZEO® Oral Suspension is a significant step toward providing another option for patients undergoing chemotherapy and, together with Helsinn, we look forward to supporting the availability of this medicine in the UK.”
About AKYNZEO®
AKYNZEO® is a 5-HT3 and NK1 receptor antagonist fixed dose combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
For additional information please see the UK Summary of Product Characteristics.
About Helsinn
Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China, and a network of trusted partners enabling a commercial presence in 90 countries.
Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. For half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously fosters innovation for its patients and embraces sustainable growth as a core element of its strategic vision.
To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X.
About Chugai Pharma Europe
Chugai Pharma Europe (CPE) is part of Chugai Pharmaceutical Co., Ltd. (Chugai), a research-based pharmaceutical company headquartered in Japan. Working closely with colleagues in Japan and partners across Europe, CPE helps bring Chugai’s innovative medicines to patients across the region. With operations in the UK, France and Germany, CPE combines Chugai’s strengths in science and technology with local expertise to support better outcomes for patients.
For more information, please visit https://www.chugai.eu/ or follow us on LinkedIn.
For more information:
Helsinn Media Contact
Sabrina Perucchi
Group Communication Manager
Tel: +41 (0) 91 985 21 21
Email: communications@helsinn.com
Chugai Pharma Europe Media Contact
Robert Mackichan
PR & Communications Lead – Europe
Tel: +44 20 8987 5600
Email: r.mackichan@chugai-pharm.co.uk
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release
Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a
DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release
Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68
Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release
Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email verdbrefamidlun@landsbankinn.is.
Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release
AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us
Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release
VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining. Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets. Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining. Sound Money: Discover how tamper-proof currency can enhance stability. Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects. Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bi